Indiana University School Of Medicine

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1903-01-01

Employees: -

Market Cap: -

Website: http://www.medicine.iu.edu

Clinical Trials

Chromoendoscopy for Ulcerative Colitis Surveillance

Completed

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Procedure: Chromoendoscopy with magnification

First Posted Date: 2006-01-10

Last Posted Date: 2011-11-22

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 100

Registration Number: NCT00274209

Locations: 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States

The Effects of Obesity and Protein Intake on the Kidney

Not Applicable

Completed

Conditions: Kidney Diseases

Interventions: Behavioral: Diet

First Posted Date: 2005-10-27

Last Posted Date: 2015-08-28

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 50

Registration Number: NCT00244790

Locations: 🇺🇸
University Hospital, Indianapolis, Indiana, United States

Dose Escalation Study for Primary Hepatocellular Carcinoma

Not Applicable

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Radiation: Stereotactic Body Radiation

First Posted Date: 2005-10-25

Last Posted Date: 2018-12-13

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 77

Registration Number: NCT00243841

Locations: 🇺🇸
Indiana University Department of Radiation Oncology, Indianapolis, Indiana, United States

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2005-10-25

Last Posted Date: 2014-03-18

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 8

Registration Number: NCT00243854

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

A Feasibility Study of Smoking Cessation Program in Radiation Oncology

Not Applicable

Completed

Conditions: Cancer and Tobacco Abuse

First Posted Date: 2005-10-12

Last Posted Date: 2007-10-31

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 36

Registration Number: NCT00236288

Locations: 🇺🇸
Indiana University, Department of Radiation Oncology, Indianapolis, Indiana, United States

Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

First Posted Date: 2005-10-10

Last Posted Date: 2017-03-03

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 30

Registration Number: NCT00235274

Locations: 🇺🇸
LaRue Carter Hospital, Indianapolis, Indiana, United States

The Role of Serotonin in Hot Flashes After Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Dietary Supplement: Acute tryptophan depletion
Dietary Supplement: Half-strength tryptophan depletion (Control)

First Posted Date: 2005-09-29

Last Posted Date: 2015-04-14

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 28

Registration Number: NCT00228943

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Clozapine augmented with atomoxetine up to 40 mg or placebo

First Posted Date: 2005-09-22

Last Posted Date: 2013-03-26

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 126

Registration Number: NCT00216281

Locations: 🇺🇸
LaRue Carter Hospital, Indianapolis, Indiana, United States

Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

Phase 2

Completed

Conditions: Obsessive Compulsive Disorder (OCD)

Interventions: Drug: RG1068 (Synthetic Human Secretin)

First Posted Date: 2005-09-22

Last Posted Date: 2024-02-23

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 12

Registration Number: NCT00216294

Locations: 🇺🇸
LaRue Carter Hospital, Indianapolis, Indiana, United States

Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

Phase 2

Terminated

Conditions: Pancreas Neoplasms

Interventions: Drug: COX-2 Inhibitor 6-8 weeks prior to surgery
Drug: COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP

First Posted Date: 2005-09-20

Last Posted Date: 2016-02-29

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 8

Registration Number: NCT00198081

Locations: 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy